News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Warns of Birth Defects with Use of Johnson & Johnson’s Topamax
March 7, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - An epilepsy drug also used to help prevent migraines can increase the risk for oral birth defects in babies born to women taking the medication, U.S. health officials said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Vaccines
ACIP Chair Questions Polio Vaccines, Values Individual Choice Over Public Benefit
January 23, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
January 22, 2026
·
2 min read
·
Nick Paul Taylor
Vaccines
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies
January 22, 2026
·
2 min read
·
Tristan Manalac
Earnings
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’
January 21, 2026
·
2 min read
·
Dan Samorodnitsky